HomeCompareUVFT vs MRK

UVFT vs MRK: Dividend Comparison 2026

UVFT yields 1000000.00% · MRK yields 2.81%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 UVFT wins by $4.7683925249533696e+36M in total portfolio value
10 years
UVFT
UVFT
● Live price
1000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.7683925249533696e+36M
Annual income
$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00
Full UVFT calculator →
MRK
Merck & Co. Inc.
● Live price
2.81%
Share price
$118.10
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$57.7K
Annual income
$10,113.78
Full MRK calculator →

Portfolio growth — UVFT vs MRK

📍 UVFT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodUVFTMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, UVFT + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
UVFT pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

UVFT
Annual income on $10K today (after 15% tax)
$85,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/yr
MRK
Annual income on $10K today (after 15% tax)
$238.95/yr
After 10yr DRIP, annual income (after tax)
$8,596.71/yr
At 15% tax rate, UVFT beats the other by $4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of UVFT + MRK for your $10,000?

UVFT: 50%MRK: 50%
100% MRK50/50100% UVFT
Portfolio after 10yr
$2.3841962624766848e+36M
Annual income
$2,383,727,347,228,033,600,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.98%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

UVFT
No analyst data
Altman Z
-49.1
Piotroski
3/9
MRK
Analyst Ratings
24
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+8.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

UVFT buys
0
MRK buys
8
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$MRK▲ Buy$1,001 - $15,0002026-02-04
Michael McCaul🏢 House$MRK▼ Sell$15,001 - $50,0002026-01-13
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-12-19
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-12-18
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-11-13
Ro Khanna🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-29
Val Hoyle🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-23
Marjorie Taylor Greene🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-28
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-08-14
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-05
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricUVFTMRK
Forward yield1000000.00%2.81%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$4.7683925249533696e+36M$57.7K
Annual income after 10y$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00$10,113.78
Total dividends collected$4.7683311610149396e+36M$29.8K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: UVFT vs MRK ($10,000, DRIP)

YearUVFT PortfolioUVFT Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$100,010,700$100,000,000.00$11,213$373.04+$100.00MUVFT
2$934,786,450,701$934,679,439,252.34$12,667$512.06+$934786.44MUVFT
3$8,165,787,108,578,292$8,164,786,887,076,042.00$14,439$708.14+$8165787108.56MUVFT
4$66,665,884,190,957,650,000$66,657,146,798,751,470,000.00$16,640$988.16+$66665884190957.63MUVFT
5$508,662,171,058,048,100,000,000$508,590,838,561,963,700,000,000.00$19,432$1,394.07+$508662171058048128.00MUVFT
6$3,627,235,248,428,489,700,000,000,000$3,626,690,979,905,457,600,000,000,000.00$23,057$1,992.90+$3.62723524842849e+21MUVFT
7$24,173,681,159,150,610,000,000,000,000,000$24,169,800,017,434,790,000,000,000,000,000.00$27,889$2,894.79+$2.417368115915061e+25MUVFT
8$150,567,402,861,454,640,000,000,000,000,000,000$150,541,537,022,614,370,000,000,000,000,000,000.00$34,518$4,286.29+$1.5056740286145463e+29MUVFT
9$876,477,100,281,847,600,000,000,000,000,000,000,000$876,315,993,160,785,800,000,000,000,000,000,000,000.00$43,912$6,494.35+$8.764771002818475e+32MUVFT
10$4,768,392,524,953,369,600,000,000,000,000,000,000,000,000$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00$57,714$10,113.78+$4.7683925249533696e+36MUVFT

UVFT vs MRK: Complete Analysis 2026

UVFTStock

UV Flu Technologies, Inc. engages in the research, development, manufacture, and sale of air purification systems and products primarily in the United States. Its flagship product is the ViraTech UV-400, which utilizes high-intensity germicidal ultraviolet radiation inside a killing chamber that goes beyond filtering to trap and destroy harmful microbes. The company also offers RX Air product line, which include HEPA based air purifiers. Its products are used in hotels, hair and nail salons, pet kennels, test labs, hospitals, restaurants, casinos, and military installations. The company was formerly known as Northwest Chariots Incorporated and changed its name to UV Flu Technologies, Inc. in November 2009. UV Flu Technologies, Inc. was founded in 2006 and is based in Lincolnshire, Illinois.

Full UVFT Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this UVFT vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

UVFT vs SCHDUVFT vs JEPIUVFT vs OUVFT vs KOUVFT vs MAINUVFT vs JNJUVFT vs ABBVUVFT vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.